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Initial development of a patient-reported instrument assessing harm,
efficacy, and misuse of long-term opioid therapy
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Abstract—Guidelines on long-term opioid therapy recommend frequent reassessment of harm, efficacy, and misuse of
these potentially harmful and sometimes ineffective medications. In primary care, there is a need for a brief, patientreported instrument. This report details the initial steps in the
development of such an instrument. An interdisciplinary team
of clinician-scientists performed four discrete steps in this
study: (1) conceptualization of the purpose and function of the
instrument, (2) assembly of an item pool, (3) expert rating on
which items were most important to include in the instrument,
and (4) modification of expert-selected items based on a reading level check and cognitive interviews with patients. A
diverse panel of 47 subject matter experts was presented with
69 items to rate on a 1–9 scale in terms of importance for inclusion in the instrument. The panel highly rated 37 items:
8 related to harm, 4 related to efficacy, and 25 related to misuse. These 37 items were then tested for patient comprehension
and modified as needed. Next steps in development will
include further item reduction, testing against a gold standard,
and assessment of the instrument’s effect on clinical outcomes.

chronic pain. Only a minority of patients may experience
benefits from long-term opioid therapy [1–2], and this
likelihood must be balanced against potential undesired
outcomes, including safety issues ranging from mild toxicities to overdose and death [3] and misuse of these potent
medications. To help patients and providers optimize outcomes and mitigate risks, experts advise a strategy of frequent reassessment of harm, efficacy, and misuse in
patients on opioids to inform treatment decisions [4–5].
Assessment of harm, efficacy, and misuse of ongoing opioid therapy can be achieved through patient report, e.g.,
querying patients about side effects and therapeutic
effects, and other methods, such as performing urine drug
testing to assess for use of unprescribed substances [6] or
querying a prescription monitoring database for evidence
of multiple prescribers [7]. While the latter strategies are
generally recommended and may be useful in the categories of harm and misuse, systematic assessment of patientreported symptoms, emphasizing those that matter to
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INTRODUCTION
Patients and providers face complex challenges
when managing long-term opioid analgesic therapy for
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patients, has been recognized as a critical and often overlooked piece of high-quality medication management in
general [8–9] and of ongoing opioid therapy in particular
[4,10].
Experts have identified the phenomenon of clinical
inertia—not making a change in therapy that may be
indicated—as one of the factors driving the ongoing
unprecedented rates of opioid prescribing [11–12]. Furthermore, there are emerging qualitative data from
patients and providers about a troubling disconnect: the
patient continues the therapy because the prescriber continues writing the prescriptions (not because the medication is effective) and the prescriber continues to write the
prescriptions because of the untested assumption that the
patient is satisfied with the treatment [13–14]. These
findings drive our hypothesis that a brief instrument, protocolized into routine follow-up, may promote a more
active surveillance approach and combat clinical inertia.
However, to date, there is no widely accepted, validated, patient-reported instrument available to monitor
the harm, efficacy, and misuse of opioid therapy prescribed for patients with chronic pain. A recent systematic review identified nine published instruments that
assessed at least one of these categories, none of which
had been tested in clinical practice [15]. This shortcoming contributed to the conclusion that none of these
instruments were comprehensive and feasible to implement in clinical practice. In light of this identified gap,
our long-term goal is to develop such an instrument. The
purpose of the present study was to describe the methods
used to develop the preliminary version of an instrument
designed to measure patient-reported harm, efficacy, and
misuse of opioid therapy that will ultimately undergo further testing.
METHODS
Overview of Study Design
We performed four discrete steps in this study: (1) conceptualization of the purpose and function of the instrument, (2) assembly of an item pool, (3) expert rating of
items from the pool most important to include in the preliminary version, and (4) modification of expert-selected
items based on a reading level check and cognitive interviews with patients. Each component of the study was
approved by the Department of Veterans Affairs (VA) Connecticut Healthcare System Human Subjects Subcommittee

and the Yale University School of Medicine’s Institutional
Review Board.
Purpose and Function of Instrument
We convened a core research team, composed of clinician researchers with diverse training and experience in primary care/internal medicine, rheumatology, psychology,
pain medicine, addiction medicine, nursing, psychometrics,
and clinical epidemiology, to discuss the identified gap in
opioid monitoring and establish the purpose and function of
a new instrument. Consensus emerged that the instrument
should be (1) developed for use in primary care, where most
long-term opioid therapy is prescribed; (2) patient-reported
and patient self-administered in order to improve efficiency
and eliminate barriers to completion; (3) designed to be sensitive to incipient or developing harms and low or absent
benefit; (4) complementary to existing measures of pain and
opioid misuse; and (5) designed such that one or more positive responses to items on the instrument would prompt a
more detailed clinical assessment of each positive response.
As such, there would be no scaling or scoring of the instrument. We plan to name the final instrument the PatientReported Indications for Opioid Reassessment (PRIOR).
Assembly of Item Pool
We first performed a systematic review to identify
instruments containing patient self-reported items related
to safety, efficacy, and misuse of opioid therapy [15] and
sorted items from these instruments (n = 9) by category
(safety, efficacy, misuse, or other). The core research
team reached consensus on whether this pool lacked any
important items by comparing the list of efficacy-related
items to the Initiative on Methods, Measurement and
Pain Assessment in Clinical Trials (IMMPACT) recommended domains for assessing analgesic efficacy in clinical trials [16] and comparing the list of harm-related
items with a literature search of opioid-related harms.
Beyond these two sources, a suitable item was identified
from the broader medical literature for any specific content area identified as missing.
Eliminating Items
First, we removed items that did not directly pertain
to harm, efficacy, or misuse of current opioid therapy.
Next, we identified items with identical or near-identical
syntax and removed those items judged to have less clear
syntax. We then removed items that were not written in
patient-reported format if the item’s content was covered
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by a similar, patient-reported item. Since interpreting the
clinical significance of single time point numeric ratings
can be challenging [17], we removed items relying on
numeric scales in the response if similar items not requiring use of a numeric rating scale were available. Finally,
in recognition that three of the instruments identified in
the systematic review were designed for clinical research
on opioid-induced constipation (the Bowel Function
Index, the Patient Assessment of Constipation Symptoms, and the Bowel Function Diary) and contained a
level of detail on constipation unnecessary for primary
care-based screening, we chose three items that adequately covered the concept of opioid-induced constipation rather than including all the constipation-related
items.
Item Modification and Standardization
If a single item contained more than one content area,
we revised it to create multiple items covering each one.
For items not written in patient-reported format and if the
content was not otherwise covered in one of the remaining
items, we modified them into patient-reported format
based on examples from the broader medical literature. To
promote ease of evaluation by the expert panel and, ultimately, use of the instrument in clinical practice, we standardized the items in three ways. First, we edited each
item to include a common stem, “In the last 30 days . . .”
to fit the planned use of the instrument multiple times per
year. With our goal of developing an instrument sensitive
to harm-related problems, asking a patient to evaluate a
symptom and additionally whether that symptom was
related to or caused by opioids seemed unnecessarily
complex and a potential source of low sensitivity. Therefore, when possible, we removed attribution of symptoms
to opioids from items when such attribution was asked of
the patient. If attribution was the crux of the question
(e.g., “Have you been bothered by side effects of opioid
pain medications?,” we did not modify the item. Last, we
transformed each item into a question with a yes/no
response, whereby the “yes” response would denote an
issue of clinical significance requiring more detailed
assessment.
Subject Matter Expert Item Rating
A priori, we defined a subject matter expert as someone who (1) believes that, at least in some instances, opioids can be safely and effectively used for the treatment
of chronic noncancer pain; (2) prescribes and manages

opioids for chronic noncancer pain; and (3) has an established clinical or research interest in chronic pain management. We used two sources to identify potential
subject matter experts: (1) the Veterans Health Administration (VHA) pain points of contact list, consisting of
pain-interested clinicians responsible for dissemination
and implementation of VHA pain-related policies at each
VHA facility nationally (n = 108), and (2) the VHA pain
research working group listserv, whose membership consists of VHA pain-relevant investigators (n = 30).
As is increasingly common, our expert item-rating
process used an Internet-based survey platform (Qualtrics; Provo, Utah). We sent an email message to potential
participants in which we provided a description of the
project, noted the voluntary nature of participation, and
embedded a link to the Web-based survey. In the survey,
there were two screening questions regarding opioid therapy for chronic noncancer pain and a short demographics
section. After describing the purpose of the instrument,
we presented the participants with 69 items, sorted by category (harm, efficacy, or misuse), and asked them to rate
each item on a 1–9 scale with respect to its importance for
inclusion in the instrument (1 = not important, 9 = very
important), based on the stated purpose of the instrument.
Participants were asked to write in any items not listed
that they believed should be included. Adapted from a
published methodology [18], we identified the highly
rated items using prespecified criteria: median response
value of 8 or 9 with agreement, defined as 70 percent of
values of 7, 8, or 9. We stipulated a priori that at least two
items from each category would need to be present in the
preliminary version of the instrument, even if they did not
meet the definition of highly rated. We planned for the
option of a second round of rating if there were new items
suggested by subject matter experts or the absence of
agreement on highly rated items.
Reading Level Check and Cognitive Interviews with
Patients
An important step in the development of a patientreported instrument, especially one that will be selfadministered, is verifying that patients understand what
the items mean [19]. To improve the comprehensibility of
the items, we undertook two additional steps with the
highly rated items: assessing the reading level of the
items and performing cognitive interviews with patients
on opioids. The reading level of each item was assessed
using the Fog Index [20], which uses a scoring system of
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reading level based on the numbers of words per sentence
and the number of polysyllabic words per paragraph.
Next, we performed cognitive interviews with patients in
which, in 1:1 sessions, each patient was asked to read
each item out loud and interpret, in his or her own words,
what each item was asking. This “think aloud” procedure
has been used in developing other patient-reported instruments [21]. Modifications were made for any item for
which there was recurrent confusion. We conducted
interviews until the most recent version was accurately
interpreted by 10 consecutive participants.
RESULTS
Assembly of Item Pool
The Figure displays how the 129 items identified in
the systematic review were reduced to the 69 items presented to the expert panel. Based on comparison to the
domains recommended by IMMPACT, no items identified
in the systematic review covered the specific efficacyrelated content areas “functional interference” and “emotional interference.” Therefore, we added one item each
from the National Institutes of Health’s Patient-Reported
Outcomes Information System item bank related to these
specific content areas [22]. Our literature review of opioidrelated harms revealed two adverse outcomes—falls [23]
and motor vehicle accidents [24]—not accounted for in the
item pool; thus, we added an item about each [25–26].
Eliminating Items
The largest group of eliminated items were not written
in patient-reported format but contained content covered
elsewhere (n = 24). As mentioned previously, for parsimony while at the same time attempting to cover this common side effect, we retained three items related to
constipation: “Have you been bothered by constipation?,”
“Have you been bothered by hard stools?,” and “Have you
been bothered by straining or squeezing to try to pass
bowel movements?,” and removed the rest (n = 20). The
next largest group of eliminated items (n = 14) was judged
as not directly pertaining to harm, efficacy, and misuse of
current opioid therapy. Several of these items were historical in nature, e.g., “Have you ever had a drug or alcohol
addiction problem?,” and thus not practical for recurring
use. Others sought to measure characteristics not directly
related to the patient’s own experience of harm, efficacy,
or misuse, for example, “Do any of your family members

disagree with your use of pain medications?” We eliminated 13 items with identical or nearly identical syntax to
another item that was retained. For example, we considered “Is anyone in your family or among your friends concerned that you might be addicted to pain medications?”
and “Family or friends have thought that I may be dependent on or addicted to opiate pain medications” nearly
identical and eliminated the latter due to ambiguity of the
term “dependent on.” Four items relying on numeric
scales, e.g., “What percentage of your pain has been
relieved during the past week?,” were eliminated.
Item Modification and Standardization
We divided items containing more than one component
into single component items: for example, “I have felt
depressed, down, or anxious” became “I have felt
depressed,” “I have felt down,” and “I have felt anxious.”
We replaced non–patient-reported items not covered elsewhere with patient-reported versions. For example, the item
“Ask patient about vomiting” was replaced by, “Have you
been bothered by vomiting?,” gleaned from a patientreported instrument for gastric dysmotility [27]. Finally, to
create binary items where a positive response was clinically
meaningful, we inserted “bothered by” to reduce the possibility that the patient would endorse the item based on a
clinically trivial level of symptoms, for example, “In the
past 30 days, have you been bothered by constipation?”
replaced, “In the past 30 days, have you been constipated?”
Subject Matter Expert Item Rating
The response rate to the survey for potential subject
matter experts was 54 percent (75/138). Of the 75
respondents, 29 did not meet subject matter expert criteria (2 did not believe that opioids could be safely and
effectively used in the treatment of chronic noncancer
pain and 27 did not prescribe and manage opioid therapy
for chronic noncancer pain). Of the 47 subject matter
experts, 23 were women (49%), half were in the 46 to
55 yr age group, and each of VHA’s 21 geographically
contiguous catchment areas was represented. The largest
group of subject matter experts was trained in general
internal medicine/family medicine/primary care (n = 19),
followed by pain/anesthesiology (n = 15), with addiction
medicine, neurology, nursing, physiatry/physical medicine and rehabilitation, psychiatry, and rheumatology
also represented. The expert panel highly rated 37 of the
69 items based on the criteria described; see Appendix 1
(available online only) for complete results of the item
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Figure.
Item pool development. IMMPACT = Initiative on Methods, Measurement and Pain Assessment in Clinical Trials.

rating process. Of the 37 highly rated items, 8 were
related to harm, 4 were related to efficacy, and 25 were
related to misuse. The median response value of each
included harm-related item was 8, except “Have you felt
sleepy or less alert when driving or operating machinery?,” which had a median response value of 9. Since
there was consensus on highly rated items and there were
no new patient-reported items suggested by the expert
panel, a second round of rating was not necessary.

In anticipation of further testing of the PRIOR in
future studies, we consulted with the lead authors of the
original instruments for permission to use their items. All
but two authors granted permission, which affected two
of the 37 items. For both items, we selected the next
highest-rated item that was similar in content.
Reading Level Check and Cognitive Interviews
The reading level check did not lead to any item
modifications because we had already shortened long
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items in a previous step by breaking down multicomponent single items into multiple single-component items.
Additionally, there was a low density of polysyllabic
words. There was, however, heterogeneity among the
items in how opioids were referred to and also whether
the term “physician” or “doctor” was used. Based on the
cognitive interviewing process, we identified “opioid
pain medication” and “doctor” as the universally understood versions of these terms. Additionally, in the cognitive interviewing process, we learned that several patients
thought the word “sedated” meant “knocked out” or
“unconscious”; therefore, we changed this term to
“overly drowsy” in keeping with other studies of centrally acting, sedating medications [28]. Following our a
priori established protocol, the cognitive interviewing
process was complete when 10 consecutive subjects
interpreted all the items in the same way without confusion, which occurred after 16 interviews. The preliminary
version of the PRIOR is contained in Appendix 2 (available online only).
DISCUSSION
Through a multistep process, we developed a preliminary version of the PRIOR, a patient-reported instrument
for identifying opioid harm, low efficacy, and misuse
among patients on long-term opioids. The PRIOR is
designed to fill a gap based on systematic review of the
literature; accordingly, we aimed for it to be comprehensive, covering harm, efficacy, and misuse; to be patientreported and patient self-administered in order to
improve efficiency and eliminate barriers to completion,
especially in primary care; and to yield clinically actionable information. Consistent with our goal of comprehensiveness, the subject matter expert panel in the present
study highly rated at least four items from each of the
harm, efficacy, and misuse categories. This spread of
items across categories, while to some degree enforced
by design, reflects the expert panel’s interest in not just
assessing traditionally provider-centered concerns (i.e.,
misuse), but also patient-centered ones (e.g., harm and
efficacy). Feasibility is yet to be established. However, at
37 items, especially the 25 items related to misuse, this
preliminary instrument is too long and will require further item reduction to be used in busy primary care practices. While several design decisions should promote the
clinical utility of the PRIOR, this will ultimately be

determined by field testing of a briefer version in subsequent studies.
The strengths of this work include, first, the rigorous
approach to understanding the current needs in opioid
monitoring through systematic review and also gathering
input from a diverse research team with broad expertise.
Second, the process for item selection brought together a
large, diverse group of subject matter experts who efficiently arrived at consensus. Finally, the standardization
of items and use of cognitive interviewing to ensure
patient comprehension were critical steps often lacking in
other instrument development processes.
A number of decisions in the design of the preliminary PRIOR deserve further discussion. The first is our
decision to disaggregate previously validated multi-item
instruments into their component items for voting by the
expert panel. We considered this consistent with our
overall conceptualization of the final PRIOR as a checklist of symptoms and behaviors in which each item would
have its own inherent meaning and, if positive, would
indicate the need for further clinical assessment. Additionally, the use of items from previously validated
instruments afforded the advantage that each item had
already been tested to some degree for patient comprehension or other validity. The next decision was to
include only VHA clinicians in the expert panel. In recognition of the fact that VHA routinely uses other related
instruments in clinical settings (e.g., the pain numerical
rating scale, Patient Health Questionnaire-2 for depression), we are designing the PRIOR for use in VHA and
thus wanted input from experts who work in the VHA
system. Finally, we included nurse practitioners and physician assistants in the expert panel since these clinicians
function as primary care providers in the VHA system
and thus can contribute the same breadth of experience
and expertise to this process.
The current study has limitations. First, while disaggregating other instruments may ultimately contribute to
a brief, feasible instrument, it is possible that accuracy
may be compromised if certain symptoms or behaviors
are better assessed with intact groups of items. We consider this an acceptable trade-off of maximizing feasibility and sensitivity but sacrificing some specificity, which
can be gained by the ensuing patient-provider discussion.
Second, patient self-report of misuse may be inaccurate,
especially when doing so may threaten future prescriptions [29], and yet over half of the preliminary PRIOR is
misuse-related. We expect that in future development
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steps, the number of misuse-related items will be reduced
markedly; it may ultimately be determined that only one
or two misuse-related items are worthwhile for use in a
patient-reported instrument and that the bulk of the relevant data would come from non–patient-reported assessments such as urine drug tests, pill counts, and querying a
prescription monitoring database.
CONCLUSIONS
As mentioned previously, next steps in this work
include item reduction and field testing. To achieve that
aim along with examining the psychometric properties of
the instrument, we plan additional data collection and
instrument analysis using Rasch methodology [30].
Patients taking opioids will self-administer the preliminary PRIOR as part of usual clinical care. Rasch analysis
uses these data to create a hierarchy of the items on a unidimensional spectrum of difficulty, allowing elimination
of misfitting and overcorrelated items and providing evidence for reliability and validity. Through this process,
patient input will be incorporated since items that are
never or very rarely endorsed will be dropped. The goal
is to develop a briefer instrument with minimal respondent burden, which we will then compare against a standardized in-depth clinical assessment, including corollary
non–patient-reported measures (e.g., urine drug testing
and querying a prescription monitoring database), and
finally test in clinical practice for its effect on harm, efficacy, and misuse-related outcomes. Our hypothesis is
that the PRIOR will add significant value to the current
standardized measures of pain intensity (e.g., the pain
numerical rating scale) and opioid harm, but this hypothesis should be tested before broad dissemination. This
preliminary version of the PRIOR provides a strong
foundation for these future efforts.
ACKNOWLEDGMENTS
Author Contributions:
Study concept and design: W. C. Becker, D. A. Fiellin, A. C. Black,
C. T. Kostovich, R. D. Kerns, L. Fraenkel.
Acquisition of data: W. C. Becker, R. D. Kerns, L. Fraenkel.
Analysis and interpretation of data: W. C. Becker, D. A. Fiellin,
A. C. Black, C. T. Kostovich, R. D. Kerns, L. Fraenkel.
Drafting of manuscript: W. C. Becker, L. Fraenkel.

Critical revision of manuscript for important intellectual content:
W. C. Becker, D. A. Fiellin, A. C. Black, C. T. Kostovich, R. D. Kerns,
L. Fraenkel.
Statistical analysis: W. C. Becker, L. Fraenkel.
Financial Disclosures: Dr. Fiellin received honoraria to serve on an
external advisory board monitoring the diversion and abuse of
buprenorphine for Pinney Associates. The other authors have declared
that no competing interests exist.
Funding/Support: Dr. Becker was supported by a VA Health Services
Research & Development Career Development Award (award 08–
276), Dr. Fraenkel was supported by the National Institute on Arthritis
and Musculoskeletal and Skin Diseases (award K24 AR060231–02),
Dr. Kerns was supported by a VA Health Services Research & Development Research Enhancement Award Program (award REA 08–266),
and Dr. Fiellin was supported by the National Institute of Drug Abuse
(grant R01-DA020576–01A1) and the National Institute on Alcohol
Abuse and Alcoholism (grant U01-AA020795–01).
Institutional Review: Each component of the study was approved by
the VA Connecticut Healthcare System Human Subjects Subcommittee and the Yale University School of Medicine’s Institutional Review
Board.
Participant Follow-Up: The authors plan to inform participants of
the publication of this study.
Disclaimer: The views expressed in this article are those of the
authors and do not necessarily reflect the position or policy of the VA
or the U.S. Government.

REFERENCES
1. Martell BA, O’Connor PG, Kerns RD, Becker WC,
Morales KH, Kosten TR, Fiellin DA. Systematic review:
opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction. Ann Intern Med.
2007;146(2):116–27. [PMID:17227935]
http://dx.doi.org/10.7326/0003-4819-146-2-20070116000006
2. Noble M, Treadwell JR, Tregear SJ, Coates VH, Wiffen PJ,
Akafomo C, Schoelles KM. Long-term opioid management
for chronic noncancer pain. Cochrane Database Syst Rev.
2010;(1):CD006605. [PMID:20091598]
3. Warner M, Chen LH, Makuc DM. Increase in fatal poisonings involving opioid analgesics in the United States,
1999–2006. NCHS data brief. Hyattsville (MD): Centers
for Disease Control and Prevention; 2009.
4. Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC,
Davies P, Donovan MI, Fishbain DA, Foley KM, Fudin J,
Gilson AM, Kelter A, Mauskop A, O’Connor PG, Passik
SD, Pasternak GW, Portenoy RK, Rich BA, Roberts RG,
Todd KH, Miaskowski C; American Pain Society-American
Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in
chronic noncancer pain. J Pain. 2009;10(2):113–30.
[PMID:19187889]

134
JRRD, Volume 53, Number 1, 2016

5. Management for Opioid Therapy for Chronic Pain Working
Group. VA/DoD clinical practice guideline for management of opioid therapy for chronic pain. Washington (DC):
Department of Veterans Affairs/Department of Defense;
2010.
6. Gourlay DL, Heit HA. Urine drug testing in pain and
addiction medicine. In: Smith HS, Passik SD, editors. Pain
and chemical dependency. New York (NY): Oxford University Press; 2008.
7. de Leon-Casasola OA. Opioids for chronic pain: New evidence, new strategies, safe prescribing. Am J Med. 2013;
126(3 Suppl 1):S3–11. [PMID:23414718]
http://dx.doi.org/10.1016/j.amjmed.2012.11.011
8. Speight J, Barendse SM. FDA guidance on patient reported
outcomes. BMJ. 2010;340:c2921. [PMID:20566597]
http://dx.doi.org/10.1136/bmj.c2921
9. Cella D, Yount S, Rothrock N, Gershon R, Cook K, Reeve
B, Ader D, Fries JF, Bruce B, Rose M; PROMIS Cooperative Group. The Patient-Reported Outcomes Measurement
Information System (PROMIS): Progress of an NIH Roadmap cooperative group during its first two years. Med
Care. 2007;45(5 Suppl 1):S3–11. [PMID:17443116]
http://dx.doi.org/10.1097/01.mlr.0000258615.42478.55
10. Chou R, Ballantyne JC, Fanciullo GJ, Fine PG, Miaskowski C. Research gaps on use of opioids for chronic noncancer pain: Findings from a review of the evidence for an
American Pain Society and American Academy of Pain
Medicine clinical practice guideline. J Pain. 2009;10(2):
147–59. [PMID:19187891]
http://dx.doi.org/10.1016/j.jpain.2008.10.007
11. Von Korff M, Kolodny A, Deyo RA, Chou R. Long-term
opioid therapy reconsidered. Ann Intern Med. 2011;
155(5):325–28. [PMID:21893626]
http://dx.doi.org/10.7326/0003-4819-155-5-20110906000011
12. Sullivan MD, Howe CQ. Opioid therapy for chronic pain in
the United States: Promises and perils. Pain. 2013;
154(Suppl 1):S94–100. [PMID:24036286]
http://dx.doi.org/10.1016/j.pain.2013.09.009
13. Lewis ET, Combs A, Trafton JA. Reasons for under-use of
prescribed opioid medications by patients in pain. Pain
Med. 2010;11(6):861–71. [PMID:20624241]
http://dx.doi.org/10.1111/j.1526-4637.2010.00868.x
14. Matthias MS, Parpart AL, Nyland KA, Huffman MA,
Stubbs DL, Sargent C, Bair MJ. The patient-provider relationship in chronic pain care: Providers’ perspectives. Pain
Med. 2010;11(11):1688–97. [PMID:21044259]
http://dx.doi.org/10.1111/j.1526-4637.2010.00980.x
15. Becker WC, Fraenkel L, Edelman EJ, Holt SR, Glover J,
Kerns RD, Fiellin DA. Instruments to assess patientreported safety, efficacy, or misuse of current opioid therapy for chronic pain: A systematic review. Pain. 2013;

154(6):905–16. [PMID:23601625]
http://dx.doi.org/10.1016/j.pain.2013.02.031
16. Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA,
Jensen MP, Katz NP, Kerns RD, Stucki G, Allen RR, Bellamy N, Carr DB, Chandler J, Cowan P, Dionne R, Galer
BS, Hertz S, Jadad AR, Kramer LD, Manning DC, Martin
S, McCormick CG, McDermott MP, McGrath P, Quessy S,
Rappaport BA, Robbins W, Robinson JP, Rothman M,
Royal MA, Simon L, Stauffer JW, Stein W, Tollett J, Wernicke J, Witter J; IMMPACT. Core outcome measures for
chronic pain clinical trials: IMMPACT recommendations.
Pain. 2005;113(1–2):9–19. [PMID:15621359]
http://dx.doi.org/10.1016/j.pain.2004.09.012
17. Fraenkel L, Falzer P, Fried T, Kohler M, Peters E, Kerns R,
Leventhal H. Measuring pain impact versus pain severity
using a numeric rating scale. J Gen Intern Med. 2012;
27(5):555–60. [PMID:22081365]
http://dx.doi.org/10.1007/s11606-011-1926-z
18. Campbell SM, Shield T, Rogers A, Gask L. How do stakeholder groups vary in a Delphi technique about primary
mental health care and what factors influence their ratings?
Qual Saf Health Care. 2004;13(6):428–34.
[PMID:15576704]
http://dx.doi.org/10.1136/qshc.2003.007815
19. Cook DA, Beckman TJ. Current concepts in validity and
reliability for psychometric instruments: Theory and application. Am J Med. 2006;119(2):166.e7–16.
[PMID:16443422]
http://dx.doi.org/10.1016/j.amjmed.2005.10.036
20. Gunning R. The technique of clear writing. New York
(NY): McGraw-Hill; 1968.
21. Watanabe S, Nekolaichuk C, Beaumont C, Mawani A. The
Edmonton symptom assessment system—What do patients
think? Support Care Cancer. 2009;17(6):675–83.
[PMID:18953577]
http://dx.doi.org/10.1007/s00520-008-0522-1
22. Amtmann D, Cook KF, Jensen MP, Chen WH, Choi S,
Revicki D, Cella D, Rothrock N, Keefe F, Callahan L, Lai
JS. Development of a PROMIS item bank to measure pain
interference. Pain. 2010;150(1):173–82. [PMID:20554116]
http://dx.doi.org/10.1016/j.pain.2010.04.025
23. Miller M, Stürmer T, Azrael D, Levin R, Solomon DH.
Opioid analgesics and the risk of fractures in older adults
with arthritis. J Am Geriatr Soc. 2011;59(3):430–38.
[PMID:21391934]
http://dx.doi.org/10.1111/j.1532-5415.2011.03318.x
24. Gomes T, Redelmeier DA, Juurlink DN, Dhalla IA, Camacho X, Mamdani MM. Opioid dose and risk of road trauma
in Canada: A population-based study. JAMA Intern Med.
2013;173(3):196–201. [PMID:23318919]
http://dx.doi.org/10.1001/2013.jamainternmed.733

135
BECKER et al. Development of PRIOR

25. Friedman SM, Munoz B, West SK, Rubin GS, Fried LP.
Falls and fear of falling: Which comes first? A longitudinal
prediction model suggests strategies for primary and secondary prevention. J Am Geriatr Soc. 2002;50(8):1329–35.
[PMID:12164987]
http://dx.doi.org/10.1046/j.1532-5415.2002.50352.x
26. Butler SF, Budman SH, Fernandez K, Jamison RN. Validation of a screener and opioid assessment measure for
patients with chronic pain. Pain. 2004;112(1–2):65–75.
[PMID:15494186]
http://dx.doi.org/10.1016/j.pain.2004.07.026
27. McNearney TA, Sallam HS, Hunnicutt SE, Doshi D, Wollaston DE, Mayes MD, Chen JD. Gastric slow waves, gastrointestinal symptoms and peptides in systemic sclerosis
patients. Neurogastroenterol Motil. 2009;21(12):1269–e120.
[PMID:19566588]
http://dx.doi.org/10.1111/j.1365-2982.2009.01350.x
28. Grushka M, Epstein J, Mott A. An open-label, dose escalation pilot study of the effect of clonazepam in burning
mouth syndrome. Oral Surg Oral Med Oral Pathol Oral
Radiol Endod. 1998;86(5):557–61. [PMID:9830647]
http://dx.doi.org/10.1016/S1079-2104(98)90345-6
29. Fishbain DA, Cutler RB, Rosomoff HL, Rosomoff RS.
Validity of self-reported drug use in chronic pain patients.

Clin J Pain. 1999;15(3):184–91. [PMID:10524471]
http://dx.doi.org/10.1097/00002508-199909000-00005
30. Bond TG, Fox CM. Applying the Rasch model: Fundamental measurement in the human sciences. Mahwah (NJ):
Psychology Press; 2013.

Submitted for publication November 16, 2014. Accepted
in revised form September 11, 2015.
This article and any supplementary material should be
cited as follows:
Becker WC, Fiellin DA, Black AC, Kostovich CT, Kerns
RD, Fraenkel L. Initial development of a patient-reported
instrument assessing harm, efficacy, and misuse of longterm opioid therapy. J Rehabil Res Dev. 2016;53(1):127–36.
http://dx.doi.org/10.1682/JRRD.2014.11.0285
ORCID: Robert D. Kerns, PhD: 0000-0001-7609-2771

